2025
Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole or Clomiphene
Johnson J, Siblini H, Al‐Hendy A, Segars J, González F, Taylor H, Singh B, Carson S, Christman G, Huang H, Dangi B, Zhang H. Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole or Clomiphene. Clinical And Translational Science 2025, 18: e70189. PMID: 40077973, PMCID: PMC11903501, DOI: 10.1111/cts.70189.Peer-Reviewed Original ResearchConceptsEpigallocatechin-3-gallateFolate levelsUterine fibroidsClinical trialsGreen tea extractAssociated with folate deficiencyPresence of MTHFRWomen of childbearing ageSerum folate levelsReduced folate levelsActive clinical trialsReproductive-age womenEffect of epigallocatechin gallateDhfr genotypeDHFR polymorphismTea extractDaily doseClomiphene citrateUnexplained infertilityFolate deficiencyChildbearing ageClinical studiesTreated womenFibroidsLetrozole
2024
Fibroids and unexplained infertility treatment with epigallocatechin gallate: a natural compound in green tea (FRIEND) – protocol for a randomised placebo-controlled US multicentre clinical trial of EGCG to improve fertility in women with uterine fibroids
Al-Hendy A, Segars J, Taylor H, González F, Siblini H, Zamah M, Alkelani H, Singh B, Flores V, Christman G, Johnson J, Huang H, Zhang H. Fibroids and unexplained infertility treatment with epigallocatechin gallate: a natural compound in green tea (FRIEND) – protocol for a randomised placebo-controlled US multicentre clinical trial of EGCG to improve fertility in women with uterine fibroids. BMJ Open 2024, 14: e078989. PMID: 38216200, PMCID: PMC10806662, DOI: 10.1136/bmjopen-2023-078989.Peer-Reviewed Original ResearchConceptsUnexplained infertilityIntrauterine inseminationInstitutional review boardCumulative live birth rateUterine fibroidsLive birth rateCause of infertilityFood and Drug AdminstrationGonadotropin hormone-releasing hormoneGreen tea extractDouble-blind clinical trialNon-surgical treatment optionsTimed intrauterine inseminationUterine fibroid sizeOvarian stimulationQuality of Life Questionnaire scoresHormone-releasing hormoneLocal institutional review boardInfertility treatmentNational Institute of Child HealthInstitute of Child HealthMiscarriage rateBirth rateReproductive-age womenEndometrial quality
2019
Associations Between Anti-Mullerian Hormone and Cardiometabolic Health in Reproductive Age Women Are Explained by Body Mass Index
Rios JS, Greenwood EA, Pavone MEG, Cedars MI, Legro RS, Diamond MP, Santoro N, Sun F, Robinson RD, Christman G, Zhang H, Huddleston HG. Associations Between Anti-Mullerian Hormone and Cardiometabolic Health in Reproductive Age Women Are Explained by Body Mass Index. The Journal Of Clinical Endocrinology & Metabolism 2019, 105: dgz012. PMID: 31586179, PMCID: PMC7024739, DOI: 10.1210/clinem/dgz012.Peer-Reviewed Original ResearchConceptsHomeostasis model assessment-insulin resistancePolycystic ovary syndromeAnti-Mullerian hormoneBody mass indexC-reactive proteinUnexplained infertilityWaist circumferenceOVA groupLipoprotein cholesterolMass indexRelationship of AMHModel assessment-insulin resistanceHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolSite-adjusted modelsAssessment-insulin resistanceAntral follicle countCardio-metabolic healthReproductive-aged womenMultivariable linear regression modelsReproductive-age womenClinical populationsLow-density lipoproteinCardiometabolic agingCardiometabolic indices
2017
Sexual function in infertile women with polycystic ovary syndrome and unexplained infertility
Diamond MP, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson PA, Christman GM, Huang H, Hansen KR, Baker V, Usadi R, Seungdamrong A, Bates GW, Rosen RM, Schlaff W, Haisenleder D, Krawetz SA, Barnhart K, Trussell JC, Santoro N, Eisenberg E, Zhang H, Network E. Sexual function in infertile women with polycystic ovary syndrome and unexplained infertility. American Journal Of Obstetrics And Gynecology 2017, 217: 191.e1-191.e19. PMID: 28455078, PMCID: PMC5657185, DOI: 10.1016/j.ajog.2017.04.034.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeFemale Sexual Function InventoryUnexplained infertilityOvary syndromeSexual Function InventorySexual functionInfertile womenSexual dysfunctionEunice Kennedy Shriver National InstituteFemale Sexual Distress ScaleTotal scoreMultiple Intrauterine GestationsFree androgen indexReproductive-age womenSexual function scoresBody mass indexFemale sexual functionFemale sexual dysfunctionSexual Distress ScaleScale total scoreAndrogenic manifestationsAndrogen indexOvarian stimulationAndrogen excessIntrauterine gestation
2014
Letrozole Versus Clomiphene for Infertility in the Polycystic Ovary Syndrome
Legro R, Brzyski R, Diamond M, Coutifaris C, Schlaff W, Casson P, Christman G, Huang H, Yan Q, Alvero R, Haisenleder D, Barnhart K, Bates G, Usadi R, Lucidi S, Baker V, Trussell J, Krawetz S, Snyder P, Ohl D, Santoro N, Eisenberg E, Zhang H. Letrozole Versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. Obstetrical & Gynecological Survey 2014, 69: 599-601. DOI: 10.1097/01.ogx.0000456355.64379.77.Peer-Reviewed Original ResearchPolycystic ovary syndromeAdverse effect profileMultiple pregnancy rateEffect profileFertility agentsAromatase inhibitorsLive birthsHigher multiple pregnancy rateLower multiple pregnancy rateSelective estrogen receptor modulatorsMale partnersNormal uterine cavityPatent fallopian tubesPrimary study outcomeCumulative live birthReproductive-age womenGood safety profileEstrogen receptor modulatorsClomiphene groupLetrozole groupClomiphene citrateRotterdam criteriaHot flushesOvary syndromeInfertile women
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply